 Beyond Air Inc NASDAQ: XAIR expects a delay in FDA approval for LungFit PH for persistent pulmonary hypertension of the newborn. Based on ongoing communications with the FDA, the company no longer believes that the U.S. commercial launch of LungFit PH will take place before December 31, 2021. 